Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P BCMA ALLO1

Next Previous
Search
Drug Profile

P BCMA ALLO1

Alternative Names: CAR T-cell therapies - Janssen/Poseida Therapeutics; P-BCMA-ALLO1; RG-6538

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Biotech; Transposagen Biopharmaceuticals
  • Developer Poseida Therapeutics; Roche
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 16 Jan 2025 P BCMA ALLO1 is still in phase-I trials for Multiple-myeloma (Second-line therapy or greater) in USA (IV) (NCT04960579)
  • 07 Dec 2024 Updated efficacy, pharmacokinetics and adverse events data from a phase I/Ib trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
  • 30 Sep 2024 Updated efficacy and adverse events data from a phase I trial in multiple myeloma released by Poseida Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top